Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | FYN | P06241 | 2/20 | 0.36 |
| ▸ | MMP9 | P14780 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3787197 | 0.83 | MAPT (0.44) | MAPTMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL10786829 | 0.81 | TSHR (0.54) | TSHRMAPTMEN1KMT2AKIF11 | |
| SCHEMBL10978453 | 0.77 | TSHR (0.45) | TSHRMAPTKIF11ALDH1A1LMNA | |
| SCHEMBL31550782 | 0.76 | ALDH1A1 (0.52) | TSHRMAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL2834212 | 0.76 | ALDH1A1 (0.52) | TSHRMAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL1146294 | 0.76 | MAPT (0.53) | TSHRMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL337809 | 0.75 | — | — | |
| SCHEMBL29368735 | 0.75 | — | — | |
| SCHEMBL12093642 | 0.74 | MAPT (0.40) | TSHRMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL9810705 | 0.74 | ALOX15 (0.38) | TSHRMAPTMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1171417-B1 | METHODS FOR PREPARING 3-ARYLOXY-3-ARYLPROPYLAMINES AND INTERMEDIATES THEREOF | LILLY CO ELI (US) | 2005-11-09 | — | — | EP | claimed |
| WO-2021043322-A1 | AZEPINO PYRIMIDINE DERIVATIVES AND MEDICAL USE THEREOF | 正大天晴药业集团南京顺欣制药有限公司 | 2021-03-11 | — | — | WO | disclosed |
| US-8791268-B2 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof for treating pain and other conditions | GRUENENTHAL GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8642775-B2 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof for treating pain and other conditions | GRUENENTHAL GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-20110184020-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof For Treating Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
| EP-2146962-A2 | NOVEL VANILLOID RECEPTOR LIGANDS AND THE USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICALS | Grünenthal GmbH (DE) | 2010-01-27 | — | — | EP | disclosed |
| US-20080262039-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof For Treating Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2008-10-23 | — | — | US | disclosed |
| WO-2008125337-A2 | NOVEL VANILLOID RECEPTOR LIGANDS AND THE USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICALS | Grünenthal GmbH (DE) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262039-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof For Treating Pain and Other Conditions | TRPV1, TRPV2, TRPV3 | TSHR 1602/4885MAPT 3443/4885MEN1 4565/4885 |
| US-20110184020-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof For Treating Pain and Other Conditions | TRPV1, TRPV2, TRPV3 | TSHR 1602/4885MAPT 3443/4885MEN1 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.